허
허승범 Chairman & CEO
C-suite M
Explore the full record of transactions filed by 허승범, Chairman & CEO. Officer active across 2 companies, notably 삼일제약. In total, 61 reports have been recorded. Activity tracked since 27 March 2026. The latest transaction was filed on 27 March 2026 (Purchase). Regulator: DART (FSS). All data is free.
Declarations 61 total
● Executives · 22 May 2026 (filed)
● 대표이사 회장 · Executives · 6 May 2026 (filed) · 삼일제약 Share DART:20260506000757 Ideal exit: 31 Jan 2027 (T+270) ● Executives · 23 Apr 2026 (filed) · 삼일제약 20,998 shares DART:20260423000702 ● 대표이사 회장 · Executives · 27 Mar 2026 · 삼일제약 5,206 shares @ ₩10,259.00 0.0000% mcap 100.0% of flow Share DART:20260327001170 Ideal exit: 22 Dec 2026 (T+270) ● Executives · 11 Mar 2026 (filed)
● Executives · 23 Feb 2026 (filed)
● Executives · 22 Jan 2026 (filed)
● Executives · 10 Apr 2025 (filed)
● Executives · 12 Mar 2025 (filed)
● 대표이사 회장 · Executives · 20 Dec 2024 (filed) · 삼일제약 Share DART:20241220000619 Ideal exit: 16 Sept 2025 (T+270) ● Executives · 20 Dec 2024 (filed) · 삼일제약 29,555 shares DART:20241220000688 ● Executives · 4 Sept 2023 (filed) · 삼일제약 29,555 shares DART:20230904000280 ● 대표이사 회장 · Executives · 10 Jul 2023 (filed) · 삼일제약 Share DART:20230710000032 Ideal exit: 5 Apr 2024 (T+270) ● 대표이사 회장 · Executives · 10 Jul 2023 (filed) · 삼일제약 Share DART:20230710000028 Ideal exit: 5 Apr 2024 (T+270) ● Executives · 21 Jun 2023 (filed) · 삼일제약 29,555 shares DART:20230621000397 ● 대표이사 회장 · Executives · 21 Jun 2023 (filed) · 삼일제약 Share DART:20230621000389 Ideal exit: 17 Mar 2024 (T+270) ● Executives · 10 May 2023 (filed) · 삼일제약 29,555 shares DART:20230510000769 ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000460 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000465 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000451 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000470 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000439 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000475 Ideal exit: 16 Jan 2024 (T+270) ● 대표이사 회장 · Executives · 21 Apr 2023 (filed) · 삼일제약 Share DART:20230421000433 Ideal exit: 16 Jan 2024 (T+270) ● Executives · 14 Mar 2023 (filed)
25 of 61 declarations
Load more (36 remaining) About 허승범 Heo Seung-beom is the chairman & CEO of Samil Pharmaceutical, where he leads the company towards innovation and growth. With extensive experience in the pharmaceutical sector, he is responsible for overall strategy and operations management. His dynamic leadership is essential in positioning Samil Pharmaceutical as a key player in the industry.